What's hot
View all perspectives
What's Hot
Psoriatic Arthritis Panel: EULAR 2025
Panelists Drs. Aurelie Najm, Eric Ruderman, Nelly Ziade, Jiha Lee and Jack Cush review highlights of PsA abstracts and sessions presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Spondyloarthritis Panel: Eular 2025
Panelists: Drs. Peter Nash, Yuz Yusof, Antoni Chan, Adela Castro and Jack Cush.
Watch video →
Steroids, Not JAKi, Are the Real Infection Risk
Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain.
Watch video →
Seronegative Arthritis Breakthroughs
Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Psoriatic Arthritis", presented at EULAR 2025 in Barcelona, Spain.
Watch video →
JAK Safety Update
Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Who/When to Treat Clinically Suspect Arthralgia
Dr. Jack Cush discusses risk stratification in Clinically suspect arthralgia; referencing EULAR2025 abstracts OP0004 (ALTO study) and OP0325 (long term Followup of ARRIA)
Watch video →
Hidradenitis Suppurativa: What Lies Beneath?
Dr. David Liew reports on abstract POS1237 presented at the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
The Value of Kidney Biopsy in Autoimmune Diseases
Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.
Read more →
Bella Mehta bella_mehta
6 months ago
What do we know about disparities in #SLE
- worse in women
- worse in non white populations
- have lower quality of care in vulnerable populations
- have worse outcomes in vulnerable populations
#EULAR2025 @rheumnow
Diagnosis itself is difficult in communities with poor access https://t.co/pcUaJ0eK65
Nelly ZIADE 🍀 Nellziade
6 months ago
#Lupus is one of the biggest social discriminators
🔺️Higher prevalence in Women
🔺️Higher prevalence in Non-Whites
🔺️More catastrophic manifestations in low socioeconomic groups
Disaster Medicine Session
Social disparities and impact on outcomes
#EULAR2025
@RheumNow https://t.co/mewR9NzXHt
Bella Mehta bella_mehta
6 months ago
Dual pandemic in Africa.
Increasing lifestyle diseases and obesity, along with infections and malnutrition.
These may be reflected in rheumatic diseases too (if they could be studied in detail)
#EULAR2025 @RheumNow https://t.co/6ulMRxX8az
David Liew drdavidliew
6 months ago
Targets for OA pain pharmacotherapies
some by the wayside:
- NGF
- TrkA
but some very much in play and exciting:
- neurotrophin-3
- TRPV1
- Nav1.7, 1.8
Fiona Watt #EULAR2025 @RheumNow https://t.co/DXDKNnVRRo
Antoni Chan MD (Prof) synovialjoints
6 months ago
In the APEX Phase 3b RCT (N=1020), guselkumab (IL-23p19 inhibitor) significantly reduced radiographic progression (ΔvdH-S 0.55 & 0.54 vs 1.35 PBO; p≤0.002) and improved ACR20 (67–68% vs 47%) at W24 in biologic-naïve PsA. Safety consistent with prior data. Abstract LB0010 https://t.co/mFDsBsCg6m
Bella Mehta bella_mehta
6 months ago
Migrant health literacy challenges - Individual interviews with participants with rheumatic diseases (interpreters used)
multiple aspects -
Individual, Providers and system level
Navigating health care systems
#EULAR2025 @RheumNow https://t.co/cWQ6jP8RZe
Antoni Chan MD (Prof) synovialjoints
6 months ago
RCT in axSpA (N=200): Digital therapeutic Axia added to stable treatment led to significant improvements in BASDAI (–1.66), BASFI (–1.12), ASQoL (–2.51), with ASAS20/40 responses of 51%/23% vs 9%/3% for usual care. Supports role of DTx in axSpA care. Abstract LB0002 @RheumNow https://t.co/oF6bjIwNIY
David Liew drdavidliew
6 months ago
LEVI-04 (neutrophin-3 inhibitor presented as #ACR24 late-breaker in knee OA)
more good efficacy data, no rapidly progressive OA safety signal.
For us clinicians: impressive impact size, esp relative to alternatives.
Finally, something that works??
#EULAR2025 OP0374 @RheumNow https://t.co/iVdlwyaqrv
David Liew drdavidliew
6 months ago
It’s a hot topic at #EULAR2025, but the messages on AI in medicine from patient-professional discussions is clear:
- potential upside massive in many domains, but
- patients still want their clinicians by their side
#EULAR2025 meeting highlights @RheumNow https://t.co/4T6gE7TeQp
Antoni Chan MD (Prof) synovialjoints
6 months ago
Great talk by @Lupusreference on Relapsing Polychondritis and a highlight of #EULAR2025. Do not forget about the articular presentations of relapsing polychondritis @RheumNow https://t.co/1xZY7VkX1z
Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown.
Dr. John Cush RheumNow
6 months ago
EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes @MCP 2/3, & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025 https://t.co/S8iA0C4pwG
Poster Hall